.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Accenture
Deloitte
Cantor Fitzgerald
Moodys
Express Scripts
US Army
Cipla
Mallinckrodt
Novartis

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,972,967

« Back to Dashboard

Which drugs does patent 5,972,967 protect, and when does it expire?


Patent 5,972,967 protects AGGRASTAT and is included in two NDAs.

This patent has forty-four patent family members in thirty-five countries.

Summary for Patent: 5,972,967

Title: Compositions for inhibiting platelet aggregation
Abstract:The invention is a pharmaceutical composition for intravenous administration to a patient comprising a) a pharmaceutically effective amount of 2-S-(n-Butylsulfonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propion ic acid; b) a pharmaceutically acceptable amount of a citrate buffer effective to provide a pH of between about 5 and 7; and c) a pharmaceutically acceptable amount of a tonicity adjusting agent effective to make the formulation substantially isotonic with the osmotic pressure of the biological system of the patient.
Inventor(s): Gelotte; Karl M. (North Wales, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:08/965,922
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
MedicureAGGRASTATtirofiban hydrochlorideINJECTABLE;INJECTION020913-002May 17, 2002RXYesNo► Subscribe► Subscribe► Subscribe
MedicureAGGRASTATtirofiban hydrochlorideINJECTABLE;INJECTION020912-001May 14, 1998DISCNNoNo► Subscribe► Subscribe► Subscribe
MedicureAGGRASTATtirofiban hydrochlorideINJECTABLE;INJECTION020913-003Apr 20, 2000RXYesYes► Subscribe► Subscribe► Subscribe
MedicureAGGRASTATtirofiban hydrochlorideINJECTABLE;INJECTION020913-001May 14, 1998DISCNNoNo► Subscribe► Subscribe► Subscribe
MedicureAGGRASTATtirofiban hydrochlorideSOLUTION;INJECTION020912-002Aug 31, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,972,967

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,733,919 Compositions for inhibiting platelet aggregation► Subscribe
5,965,581 Compositions for inhibiting platelet aggregation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,972,967

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina004223► Subscribe
Austria213648► Subscribe
Australia712755► Subscribe
Australia7718996► Subscribe
Bulgaria102405► Subscribe
Bulgaria63623► Subscribe
Brazil9610878► Subscribe
Canada2234364► Subscribe
China1158107► Subscribe
China1200676► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Daiichi Sankyo
Julphar
Fuji
US Army
Covington
Chinese Patent Office
Johnson and Johnson
Harvard Business School
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot